Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Price Target at $10.80

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) have been assigned an average recommendation of "Buy" from the five research firms that are covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have issued a report on the stock in the last year is $10.80.

Several research firms recently issued reports on AMRX. StockNews.com cut shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, December 19th. Barclays increased their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $9.00 to $12.00 in a research note on Monday, February 24th.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 62,590 shares of the stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $8.01, for a total value of $501,345.90. Following the sale, the director now directly owns 1,968,886 shares of the company's stock, valued at $15,770,776.86. This trade represents a 3.08 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the transaction, the insider now directly owns 48,578,209 shares of the company's stock, valued at approximately $405,628,045.15. This trade represents a 9.33 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,240,000 shares of company stock worth $43,754,000. 26.56% of the stock is currently owned by insiders.

Remove Ads

Institutional Trading of Amneal Pharmaceuticals

Several hedge funds have recently bought and sold shares of AMRX. California State Teachers Retirement System grew its position in Amneal Pharmaceuticals by 10.3% in the 4th quarter. California State Teachers Retirement System now owns 131,713 shares of the company's stock worth $1,043,000 after purchasing an additional 12,282 shares during the last quarter. Phocas Financial Corp. boosted its position in shares of Amneal Pharmaceuticals by 31.1% during the fourth quarter. Phocas Financial Corp. now owns 1,330,413 shares of the company's stock worth $10,537,000 after buying an additional 315,223 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Amneal Pharmaceuticals in the 4th quarter valued at approximately $52,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Amneal Pharmaceuticals by 45.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 318,420 shares of the company's stock valued at $2,522,000 after acquiring an additional 99,866 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its position in Amneal Pharmaceuticals by 540.5% during the 4th quarter. Squarepoint Ops LLC now owns 124,744 shares of the company's stock worth $988,000 after acquiring an additional 105,268 shares during the period. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Trading Up 0.1 %

NASDAQ:AMRX traded up $0.01 on Tuesday, reaching $8.28. The stock had a trading volume of 1,273,414 shares, compared to its average volume of 1,371,248. The company has a 50-day moving average of $8.42 and a 200 day moving average of $8.37. The stock has a market cap of $2.57 billion, a P/E ratio of -12.18 and a beta of 1.05. Amneal Pharmaceuticals has a 12-month low of $5.18 and a 12-month high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The business had revenue of $730.52 million for the quarter, compared to analyst estimates of $708.21 million. During the same quarter last year, the business earned $0.14 EPS. On average, equities analysts predict that Amneal Pharmaceuticals will post 0.53 EPS for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.